Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.
• 35-75 years of age (including 35 and 75 years)
• Willingness and ability to give written informed consent
• Patients with severe chronic ischemic heart failure
• New York Heart Association (NYHA) Class III or IV under optimal medical therapy
• Weakening or absence of segmental regional wall motion as determined by standard imaging.
• LVEF≤40% as assessed by MRI
• Nuclide-myocardial metabolic perfusion imaging revealed infarcted myocardium in the left anterior descending branch (LAD) coronary artery supply area
• Patients have indications for Coronary Artery Bypass Grafting